Lurasidone-Induced Tardive Syndrome.
drug‐induced movements
dystonia
lurasidone
parkinsonism
tardive dyskinesia
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
08
04
2019
revised:
20
06
2019
accepted:
24
06
2019
entrez:
21
9
2019
pubmed:
21
9
2019
medline:
21
9
2019
Statut:
epublish
Résumé
Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS. Case series. We describe 4 patients who developed tardive dystonia, tardive akathisia, and drug-induced parkinsonism with the use of the atypical antipsychotic, lurasidone, which was U.S. Food and Drug Administration approved in 2013 for use in bipolar disorder and schizophrenia. Movement disorders are reported as a rare side effect of lurasidone, and, as such, prescribers may perceive a false sense of security regarding this potential complication. Our cases indicate that this relatively new atypical antipsychotic may cause irreversible disabling TS as well as parkinsonism. Caution must be taken when prescribing lurasidone.
Identifiants
pubmed: 31538095
doi: 10.1002/mdc3.12812
pii: MDC312812
pmc: PMC6749798
doi:
Types de publication
Case Reports
Langues
eng
Pagination
601-604Références
Mov Disord. 2008 Feb 15;23(3):401-4
pubmed: 18067180
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81
pubmed: 20404009
Neuropsychopharmacology. 2011 Jul;36(8):1738-46
pubmed: 21508932
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Parkinsonism Relat Disord. 2014 Aug;20(8):808-14
pubmed: 24935237
Tremor Other Hyperkinet Mov (N Y). 2014 Oct 23;4:266
pubmed: 25374768
Pharmacol Rep. 2016 Aug;68(4):748-55
pubmed: 27203278
J Clin Psychiatry. 2017 Mar;78(3):e264-e278
pubmed: 28146614
J Neurol Sci. 2018 Jun 15;389:35-42
pubmed: 29506749